Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders

Expert Opinion on Investigational Drugs

Volumn 19, Issue 4, 2010, Pages 513-520

  Inoue, Ken Ichiro ^a   Takano, Hirohisa ^a  

^a NATIONAL INSTITUTE FOR ENVIRONMENTAL STUDIES   (Japan)

Author keywords

Cytokine; Inflammation; Lipopolysaccharide; Urinary trypsin inhibitor

Indexed keywords

AMPHOTERICIN B; ARACHIDONIC ACID; DOPAMINE; GABEXATE MESILATE; LIPOPOLYSACCHARIDE; ULINASTATIN; AUTACOID; ENDOTOXIN; GLYCOPROTEIN;

ACUTE LUNG INJURY; ACUTE PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FATTY ACID METABOLISM; HEMODYNAMICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; INTERSTITIAL PNEUMONIA; LIPID METABOLISM; LIPID PEROXIDATION; LIVER INJURY; LIVER PROTECTION; LUNG ASPERGILLOSIS; NONHUMAN; PANCREATITIS; PROTEIN EXPRESSION; PROTHROMBIN TIME; REVIEW; SHOCK; SIGNAL TRANSDUCTION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TRANSIENT ISCHEMIC ATTACK; AMINO ACID SEQUENCE; ANIMAL; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; KNOCKOUT MOUSE; LIVER FAILURE, ACUTE; MOLECULAR GENETICS; MOUSE; PATHOLOGY; PHYSIOLOGY; SHOCK, SEPTIC; TOXICITY; TRANSGENIC MOUSE;

ACUTE LUNG INJURY; AMINO ACID SEQUENCE; ANIMALS; DISEASE MODELS, ANIMAL; ENDOTOXINS; GLYCOPROTEINS; HUMANS; INFLAMMATION MEDIATORS; LIVER FAILURE, ACUTE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; SHOCK, SEPTIC;

EID: 77952492404     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003649533     Document Type: Review

References (74)

1. Jonsson-Berling BM, Ohlsson K, Rosengren M. Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. Biol Chem Hoppe Seyler 1989;370:1157-1161
2. Nishiyama T, Aibiki M, Hanaoka K. The effect of ulinastatin, a human prote ase inhibitor, on the transfusion-induced increase of plasma polymorpho-nuclear granulocyte elastase. Anesth Analg 1996;82:108-112
3. Ohnishi H, Kosuzume H, Ashida Y, et al. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis. Dig Dis Sci 1984;29:26-32
4. Okabe H, Irita K, Kurosawa K, et al. Increase in the plasma concentration of reduced glutathione observed in rats with liver damage induced by lipopolysaccha-ride/D-galactosamine: effects of ulinastatin, a urinary trypsin inhibitor. Circ Shock 1993;41:268-272
5. Salier JP, Rouet P, Raguenez G, Daveau M. The inter-alpha-inhibitor family: from structure to regulation. Biochem J 1996;315:1-9
6. Sjoberg EM, Fries E. Biosynthesis of bikunin (urinary trypsin inhibitor) in rat hepatocytes. Arch Biochem Biophys 1992;295:217-222
7. Thogersen IB, Enghild JJ. Biosynthesis of bikunin proteins in the human carcinoma cell line HepG2 and in primary human hepatocytes. Polypeptide assembly by glycosaminoglycan. J Biol Chem 1995;270:18700-18709
8. Heron A, Bourguignon J, Calle A, et al. Post-translational processing of the inter-alpha-trypsin inhibitor in the human hepatoma HepG2 cell line. Biochem J 1994;302:573-580
9. Heron A, Bourguignon J, Diarra-Mehrpour M, et al. Involvement of the three inter-alpha-trypsin inhibitor (ITI) heavy chains in each member of the serum ITI family. FEBS Lett 1995;374:195-198
10. Ohnishi H, Suzuki K, Hiho T, et al. Protective effects of urinary trypsin inhibitor in experimental shock. Japan J Pharmacol 1985;39:137-144 (Pubitemid 16234251)
11. Albani D, Balduyck M, Mizon C, Mizon J. Inter-alpha-inhibitor as marker for neutrophil proteinase activity: an in vitro investigation. J Lab Clin Med 1997;130:339-347
12. Balduyck M, Albani D, Jourdain M, et al. Inflammation-induced systemic proteolysis of inter-alpha-inhibitor in plasma from patients with sepsis. J Lab Clin Med 2000;135:188-198
13. Mizon C, Piva F, Queyrel V, et al. Urinary bikunin determination provides insight into proteinase/proteinase inhibitor imbalance in patients with inflammatory diseases. Clin Chem Lab Med 2002;40:579-586
14. Hirose J, Ozawa T, Miura T, et al. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 1998;21:651-656
15. Balduyck M, Mizon J. Inter-alpha-trypsin inhibitor and its plasma and urine derivatives. Ann Biol Clin (Paris) 1991;49:273-281
16. Pugia MJ, Valdes R Jr, Jortani SA. Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement. Adv Clin Chem 2007;44:223-245
17. Kobayashi H, Suzuki M, Tanaka Y, et al. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C-and MEK/ERK/c-Jun-depen-dent signaling pathways. J Biol Chem 2001;276:2015-2022
18. Kobayashi H, Gotoh J, Terao T. Urinary trypsin inhibitor efficiently inhibits uro-kinase production in tumor necrosis factor-stimulated cells. Eur J Cell Biol 1996;71:380-386 (Pubitemid 26420048)
19. Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endo-scopic retrograde cholangiopancreatogra-phy: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005;3:376-383
20. Endo S, Inada K, Yamashita H, et al. The inhibitory actions of protease inhibitors on the production of polymorpho-nuclear leukocyte elastase and interleukin 8. Res. Commun Chem Pathol Pharmacol 1993;82:27-34
21. Nakatani K, Takeshita S, Tsujimoto H, et al. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001;69:241-247
22. Aosasa S, Ono S, Mochizuki H, et al. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001;15:101-105
23. Endo S, Inada K, Taki K, et al. Inhibitory effects of ulinastatin on the production of cytokines: implications for the prevention of septicemic shock. Clin Ther 1990;12:323-326
24. Maehara K, Kanayama N, Halim A, et al. Down-regulation of interleukin-8 gene expression in HL60 cell line by human Kunitz-type trypsin inhibitor. Biochem Biophys Res Commun 1995;206:927-934
25. Nakamura H, Abe S, Shibata Y, et al. Inhibition of neutrophil elastase-induced interleukin-8 gene expression by urinary trypsin inhibitor in human bronchial epithelial cells. Int Arch
26. Allergy Immunol 1997;112:157-62
27. Matsuzaki H, Kobayashi H, Yagyu T, et al. Bikunin inhibits lipopolysaccharide-induced tumor necrosis factor alpha induction in macrophages. Clin Diagn Lab Immunol 2004;11:1140-1147
28. Aibiki M, Cook JA. Ulinastatin, a human trypsin inhibitor, inhibits endotoxin-induced thromboxane B2 production in human monocytes. Crit Care Med 1997;25:430-434
29. Cook JA, Geisel J, Temple GE, et al. Endotoxin activation of eicosanoid production by macrophages. In: Schlag F, Redl H, editors, Pathophysiology of shock, sepsis and organ failure. Springer-Verlag, Heidelberg, Germany; 1993. p. 518-530
30. Molor-Erdene P, Okajima K, Isobe H, et al. Urinary trypsin inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-alpha production through inhibition of Egr-1 expression. Am J Physiol Heart Circ Physiol 2005;288:H1265-71
31. Okano S, Tagawa M, Urakawa N, Ogawa R. A therapeutic effect of ulinas-tatin on endotoxin-induced shock in dogs-comparison with methylpredniso-lone. J Vet Med Sci 1994;56:645-649
32. Tani T, Aoki H, Yoshioka T, et al. Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomized, controlled trial. Crit Care Med 1993;21:925-930
33. Wakahara K, Kobayashi H, Yagyu T, et al. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor-alpha and interleukin-1 beta in macrophages. J Infect Dis 2005;191:930-938
34. Molor-Erdene P, Okajima K, Isobe H, et al. Inhibition of lipopolysaccharide-induced tissue factor expression in mono-cytes by urinary trypsin inhibitor in vitro and in vivo. Thromb Haemost 2005;94:136-145
35. Masuda T, Sato K, Noda C, et al. Protective effect of urinary trypsin inhibitor on myocardial mitochondria during hemorrhagic shock and reperfusion. Crit Care Med 2003;31:1987-1992
36. Aihara T, Shiraishi M, Hiroyasu S, et al. Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by downregulating TNF-alpha in the liver. Transplant Proc 1998;30:3732-3734
37. Nakahama H, Obata K, Sugita M. Ulinastatin ameliorates acute ischemic renal injury in rats. Ren Fail 1996;18:893-898
38. Cao ZL, Okazaki Y, Naito K, et al. Ulinastatin attenuates reperfusion injury in the isolated blood-perfused rabbit heart. Ann Thorac Surg 2000;69:1121-1126
39. Binns OA, DeLima NF, Buchanan SA, et al. Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. J Thorac Cardiovasc Surg 1996;112:607-613
40. Okuhama Y, Shiraishi M, Higa T, et al. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res 1999;82:34-42
41. Yamaguchi Y, Ohshiro H, Nagao Y, et al. Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res 2000;94:107-115
42. Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006;34:1351-1357
43. Nishiyama T, Yokoyama T, Yamashita K. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery. J Anesth 2006;20:179-182
44. Kurosawa S, Kanaya N, Fujimura N, et al. Effects of ulinastatin on pulmonary artery pressure during abdominal aortic aneurysmectomy. J Clin Anesth 2006;18:18-23
45. Yano T, Anraku S, Nakayama R, Ushijima K. Neuroprotective effect of urinary trypsin inhibitor against focal cerebral ischemia-reperfusion injury in rats. Anesthesiology 2003;98:465-473
46. Umeki S, Tsukiyama K, Okimoto N, Soejima R. Urinastatin (Kunitz-type pro-teinase inhibitor) reducing cisplatin neph-rotoxicity. Am J Med Sci 1989;298:221-226
47. Ishigami M, Eguchi M, Yabuki S. Beneficial effects of the urinary trypsin inhibitor urinastatin on renal insults induced by gentamicin and mercuric chloride (HgCl2) poisoning. Nephron 1991;58:300-305
48. Kobayashi H, Ohi H, Terao T. Prevention by urinastatin of cis-diammi-nedichloroplatinum-induced nephrotoxi-city in rabbits: comparison of urinary enzyme excretions and morphological alterations by electron microscopy. Asia Oceania J Obstet Gynaecol 1991;17:277-288
49. Yamasaki F, Ishibashi M, Nakakuki M, et al. Protective action of ulinastatin against cisplatin nephrotoxicity in mice and its effect on the lysosomal fragility. Nephron 1996;74:158-167
50. Ishibashi M, Yamasaki F, Nakakuki M, et al. Cytoprotective effect of ulinastatin on LLC-PK1 cells treated with antimycin A, gentamicin, and cisplatin. Nephron 1997;76:300-306
51. Koizumi R, Kanai H, Maezawa A, et al. Therapeutic effects of ulinastatin on experimental crescentic glomerulonephri-tis in rats. Nephron 2000;84:347-353
52. Huang Y, Xie K, Zhang J, et al. Prospective clinical and experimental studies on the cardioprotective effect of ulinastatin following severe burns. Burns 2008;34:674-680
53. Tsujimura S, Saito K, Nakayamada S, Tanaka Y. Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. Mod Rheumatol 2005;15:374-380
54. Komori M, Takada K, Tomizawa Y, et al. Urinary trypsin inhibitor improves peripheral microcirculation and broncho-spasm associated with systemic anaphy-laxis in rabbits in vivo. Shock 2003;20:189-194
55. Inamo Y, Okubo T, Wada M, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol 2002;127:89-94
56. Harashima S, Tsukamoto H, Nishizaka H, et al. Successful treatment of invasive pulmonary aspergillosis by transbronchial injection of urinary trypsin inhibitor and amphotericin B. Acta Haematol 2003;109:156-157
57. Sato A, Kuwabara Y, Shinoda N, et al. Use of low dose dopamine, gabexate mesilate and ulinastatin reduces the water balance and pulmonary complication in thoracic esophagectomy patients. Dis Esophagus 2005;18:151-154
58. Kobayashi H, Suzuki M, Tanaka Y, et al. A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade. J Biol Chem 2003;278:7790-7799
59. Kobayashi H, Yagyu T, Inagaki K, et al. Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer. Cancer 2004;100:869-877
60. Suzuki M, Kobayashi H, Tanaka Y, et al. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin. Int J Cancer 2003;104:289-302
61. Yoshioka I, Tsuchiya Y, Aozuka Y, et al. Urinary trypsin inhibitor suppresses surgical stress-facilitated lung metastasis of murine colon 26-L5 carcinoma cells. Anticancer Res 2005;25:815-820
62. Kobayashi H, Suzuki M, Kanayama N, et al. Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. Eur J Biochem 2002;269:3945-3957
63. Kobayashi H, Suzuki M, Hirashima Y, Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 2003;384:749-754
64. Kobayashi H. Suppression of urokinase expression and tumor metastasis by bikunin overexpression [mini-review]. Hum Cell 2001;14:233-236
65. Sato H, Kajikawa S, Kuroda S, et al. Impaired fertility in female mice lacking urinary trypsin inhibitor. Biochem Biophys Res Commun 2001;281:1154-1160
66. Inoue K, Takano H, Shimada A, et al. Urinary trypsin inhibitor protects against systemic inflammation induced by lipo-polysaccharide. Mol Pharmacol 2005;67:673-680
67. Ito K, Mizutani A, Kira S, et al. Effect of Ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of activated leukocytes. Injury 2005;36:387-394
68. Inoue K, Takano H, Yanagisawa R, et al. Protective role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide. Exp Biol Med (May-wood) 2005;230:281-287
69. Inoue K, Takano H, Yanagisawa R, et al. Antioxidative role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide. Int J Mol Med 2005;16:1029-1033
70. Lin SD, Endo R, Sato A, et al. Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis. J Gastroenterol Hepatol 2002;17:140-147
71. Lin SD, Endo R, Kuroda H, et al. Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:327-332
72. Takano H, Inoue K, Shimada A, et al. Urinary trypsin inhibitor protects against liver injury and coagulation pathway dysregulation induced by lipopolysaccharide/D-galactosamine in mice. Lab Invest 2009;89:833-839
73. Inoue KI, Takano H, Sato H, et al. Protective role of urinary trypsin inhibitor in lung expression of proinflamma-tory cytokines accompanied by lethal liver injury in mice. Immunopharmacol Immunotoxicol 2009;31:446-450
74. Nobuoka T, Mizuguchi T, Oshima H, et al. Impaired liver regeneration with humoral and genetic disturbances in urinary trypsin inhibitor-deficient mice. Liver Int 2009;29:979-987